What is the optimal dose of adipose-derived mesenchymal stem cells treatment for knee osteoarthritis? A conventional and network meta-analysis of randomized controlled trials

Huang, Zongyuan; Zhang, Shuai; Cao, Mingde; Lin, Zhujian; Kong, Ling; Wu, Xin; Guo, Qianshi; Ouyang, Yuxiang; Song, Yancheng

doi:10.1186/s13287-023-03475-5

Stem Cell Research & Therapy

Table 1 Basic characteristics of the literature included in the study

From: What is the optimal dose of adipose-derived mesenchymal stem cells treatment for knee osteoarthritis? A conventional and network meta-analysis of randomized controlled trials

References	Study	Country	Origin	Cell doses	Kellgren–Lawrence grade	Sample size (M/F)		Mean age (years)		Follow-up (month)	Relevant outcomes
References	Study	Country	Origin	Cell doses	Kellgren–Lawrence grade	Trial group	Control group	Trial group	Control group	Follow-up (month)	Relevant outcomes
[12]	Freitag et al., (1) 2019	Australia	AD-MSCs	100 × 10⁶	II,III	10 (7/3)	10 (5/5)	54.60 ± 8.10	51.10 ± 6.10	1, 3, 6, 12	①③④⑦
	Freitag et al., (2) 2019	Australia	AD-MSCs	100 × 10⁶	II,III	10 (4/6)	10 (5/5)	54.60 ± 8.10	51.10 ± 6.10	1, 3, 6, 12	①③④⑦
[13]	Garza et al., (1) 2020	USA	AD-MSCs	15 × 10⁶	II,III	13 (4/9)	13 (6/7)	60.50 ± 7.90	57.10 ± 9.10	6, 12	①④⑦
	Garza et al., (2) 2020	USA	AD-MSCs	30 × 10⁶	II,III	13 (6/7)	13 (6/7)	59.50 ± 11.70	57.10 ± 9.10	6, 12	①④⑦
[14]	Koh et al., 2012	South Korea	AD-MSCs	1.89 × 10⁶	II,III, IV	25 (8/17)	25 (8/17)	54.20 ± 9.30	54.40 ± 11.30	3, 12	②⑧⑦
[15]	Lee et al., 2019	South Korea	AD-MSCs	100 × 10⁶	II,III, IV	12 (3/9)	12 (3/9)	62.20 ± 6.50	63.20 ± 4.20	1, 3, 6	①②③④⑥⑦
[16]	Lu et al., 2019	China	AD-MSCs	50 × 10⁶	I,II,III	26 (3/23)	26 (3/23)	55.03 ± 9.19	55.03 ± 9.19	6, 12	①②④⑥⑦
[17]	Jo et al., (1) 2017	Korea	AD-MSCs	10 × 10⁶	III, IV	3	–	61.80 ± 6.60	–	1, 2, 3, 6, 12, 24	①②③④
	Jo et al., (2) 2017	Korea	AD-MSCs	50 × 10⁶	III, IV	3	–	61.80 ± 6.60	–	1, 2, 3, 6, 12, 24	①②③④
	Jo et al., (3) 2017	Korea	AD-MSCs	100 × 10⁶	III, IV	12	–	61.80 ± 6.60	–	1, 2, 3, 6, 12, 24	①②③④
[18]	Kuah et al., (1) 2018	Australia	AD-MSCs	3.9 × 10⁶	I,II,III	8 (8/2)	4 (1/3)	52.90 ± 6.47	55.00 ± 10.42	1, 3, 6, 9, 12	①②④
	Kuah et al., (1) 2018	Australia	AD-MSCs	6.7 × 10⁶	I,II,III	8 (5/3)	4 (1/3)	52.90 ± 6.47	55.00 ± 10.42	1, 3, 6, 9, 12	①②④
[19]	Chen et al., (1) 2021	China	AD-MSCs	16 × 10⁶	I,II,III	17 (3/17)	8 (3/5)	67.70 ± 6.84	70.50 ± 8.37	1, 3, 6, 12, 24	①②
	Chen et al., (2) 2021	China	AD-MSCs	32 × 10⁶	I,II,III	17 (2/15)	8 (3/5)	68.60 ± 6.45	70.50 ± 8.37	1, 3, 6, 12, 24	①②
	Chen et al., (3) 2021	China	AD-MSCs	64 × 10⁶	I,II,III	15 (3/12)	8 (3/5)	64.90 ± 4.91	70.50 ± 8.37	1, 3, 6, 12, 24	①②
[20]	Bastos et al., 2019	Portugal	BM-MSCs	40 × 10⁶	I,II,III,IV	16 (10/6)	17 (9/8)	55.70 ± 7.8	55.90 ± 13.4	1, 2, 3, 6, 9, 12	⑦
[21]	Lamo‑Espinos et al., (1) 2016	Spain	BM-MSCs	10 × 10⁶	II,III,IV	10 (4/6)	10 (7/3)	65.90 ± 8.22	60.30 ± 4.44	3, 6, 12	①②④
	Lamo‑Espinos et al., (1) 2016	Spain	BM-MSCs	100 × 10⁶	II,III,IV	10 (8/2)	10 (7/3)	57.80 ± 4.29	60.30 ± 4.44	3, 6, 12	①②④
[22]	Emadedin et al., 2018	Iran	BM-MSCs	40 × 10⁶	II,III,IV	19(12/7)	24(15/9)	51.70 ± 9.20	54.70 ± 5.30	3, 6	③
[23]	Vega et al., 2015	Spain	BM-MSCs	40 × 10⁶	II,III,IV	15 (9/6)	15 (10/6)	56.60 ± 9.24	57.33 ± 9.09	3, 6, 12	①②④⑦
[24]	Guptaet al.,l (1) 2016	India	BM-MSCs	25 × 10⁶	II,III,IV	10 (3/7)	10 (0/10)	58.10 ± 8.23	55.80 ± 6.78	1, 3, 6, 12	①②④⑦
	Guptaet al.,l (2) 2016	India	BM-MSCs	50 × 10⁶	II,III,IV	10 (2/8)	10 (0/10)	57.30 ± 9.45	55.80 ± 6.78	1, 3, 6, 12	①②④⑦
	Gupta et al., (3) 2016	India	BM-MSCs	75 × 10⁶	II,III,IV	10 (8/2)	10 (7/3)	55.00 ± 6.72	56.70 ± 5.19	1, 3, 6, 12	①②④⑦
	Gupta et al., (4) 2016	India	BM-MSCs	150 × 10⁶	II,III,IV	10 (5/5)	10 (7/3)	54.00 ± 6.73	56.70 ± 5.19	1, 3, 6, 12	①②④⑦
[25]	Matas et al., (1) 2019	Chile	UC-MSCs	20 × 10⁶	I,II,III	10 (4/6)	9 (4/5)	56.10 ± 6.80	54.80 ± 4.50	1, 2, 3, 4, 6, 9, 12	①②④⑦
	Matas et al., (1) 2019	Chile	UC-MSCs	20 × 10⁶	I,II,III	10 (5/5)	9 (4/5)	56.70 ± 4.10	54.80 ± 4.50	1, 2, 3, 4, 6, 9, 12	①②④⑦
[26]	Ha et al., 2018	China	UC-MSCs	5 × 10⁶	I,II,III	43 (12/32)	43 (11/32)	57.00 ± 3.20	56.20 ± 6.70	1, 3, 6, 12	②④⑤⑦
[27]	Yang et al., (1) 2017	China	UC-MSCs	30 × 10⁶	III,IV	15 (3/12)	16 (5/11)	70.60 ± 20.10	72.20 ± 17. 80	3, 6, 12	①
	Yang et al., (1) 2017	China	UC-MSCs	60 × 10⁶	III,IV	13 (3/10)	16 (5/11)	71.50 ± 16.30	72.20 ± 17. 80	3, 6, 12	②

① WOMAC, ② VAS, ③ KOOS, ④ MRI, ⑤ AKS, ⑥ SF-36, ⑦ AEs, ⑧ Lysholm; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; VAS, Visual Analog Scale; KOOS, Knee Osteoarthritis Outcome Score; SF-36, Short Form-36 health survey; AKS, American Knee Society; AEs, adverse effects; AD-MSCs, adipose-derived mesenchymal stem cells, BM-MSCs, bone marrow mesenchymal stem cells; UC-MSCs, umbilical cord mesenchymal stem cells

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com